Eli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on average. While both drugs showed significant weight loss benefits, Zepbound's results were more promising. However, experts stress the importance of additional studies on broader health benefits such as heart disease risk reduction. Eli Lilly’s stock surged following the announcement, bolstering the market share of Zepbound.
